Don’t even consider a buy out... We have the potential

New Post Public Reply Private Reply Replies (0) Message Board
Goosebumps blafarm #25593
465
Don’t even consider a buy out... We have the potential for as many as 4 FDA approvals this year and maybe more if you consider all 22 cancer indications as separate. Revenue is astronomical worldwide if that happens. Accepting an offer now before the revenue goes ballistic is just plain foolishness. We might be buying out Gilead or Merck down the road. We might be the biggest drug to ever hit the market. Why would anyone consider giving up that opportunity? You ran a few numbers but it doesn’t seem like you ran enough numbers to include the world market in those numbers.

If someone were to break down every indication for the USA and the rest of the world it is just as NP has stated. You must forget that he is a engineer and math is a strong subject for him. He has stated that this is not only a 3 digit stock in a couple of years but a high 3 digit stock or quite possibly 4 digit. I believe that he has stayed up late on sleepless night and worked the figures himself to know just what the potential is for this drug and it’s many indications. I hope to always be invested in this company and would never sell out for pennies on the dollar. You have to understand that the potential is beyond what anybody here on this board has worked out. It’s not that far from the biggest returns either.

NP stated not long ago that when MTNBC has FDA approval then How far is it to stretch that to all 22 other cancers since they have the same mechanism of action. Dr. Patterson will be instrumental in explaining the mechanism of action to the FDA. Nader is basically saying that they should be approved all together since it works the same for all indications. I agree with that statement. Even if he has to get approval on each separately which I can’t understand why the FDA would not approve. But even if they don’t the market is there to start prescribing for different cancers even if not approved. You just need one approval and the door opens to all of them for different indications. So don’t accept pennies on the dollar. Sell some stock here and there as the value goes astronomical and wait for the golden parachute at the end when you get to enjoy the fruits of your patience...

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BTQ's MIMIQ: A Quantum Leap for 35,000 Developers

Updated Category News Views 17

Breaking Barriers in Quantum Emulation If you think the quantum computing game is all about hardware, then you're missing half the picture. Enter BTQ Technologies, crash-landing into the scene by throwing open the doors of their MIMIQ emulator to a crowd of over 35,000 quantum developers through qBraid. This ain't just an upgrade—it's a seismic shift. More qubits, more...

Continue Reading
SoftwareOne Triumphs in 2026 GitHub Partner Awards

Updated Category News Views 55

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

Continue Reading
PBM Transparency Rule: Game Changer for 136M Americans

Updated Category News Views 23

Turning the Tide on Pharmacy Costs The world of pharmacy benefits is getting a long-overdue shake-up, courtesy of a new rule mandating transparency from the pharmacy benefit managers (PBMs). This ain't your everyday administrative tweak—it's a seismic shift for the 136 million Americans tied into employer-sponsored health plans. Thanks to the U.S. Department of Labor...

Continue Reading
Yale's $10M Inflammation Initiative: Future Health Impact

Updated Category News Views 0

Yale’s Inflammation Research: Beyond the Basics Inflammation. It’s the kind of battle your own body wages from within, and Yale School of Medicine’s fresh $10 million grant from the Blavatnik Family Foundation means they’re marching deeper into the trenches. This is not another academic exercise; it’s about digging out the roots of diseases that are tough to pin...

Continue Reading
TIOmarkets App Unveils Enhanced Trading Features

Updated Category News Views 32

Trading on the Go Takes a Leap Forward Pretty slick development from TIOmarkets, if I do say so myself. They've rolled out a major expansion of their mobile trading app, now packing some hefty features like Depth of Market and more granular order controls right from those little devices in our pockets. Quite the leap if you're one of those folks who can't keep your eyes...

Continue Reading
Data Breach at Lumara Bio: Privacy Lawsuits Loom

Updated Category News Views 217

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Continue Reading
Equitable Bank Bumps Rates Amid Market Shuffle

Updated Category News Views 57

Equitable Bank Dials Up Its Prime Rate Equitable Bank's taken a step that every borrower and investor out there can't ignore: they've hiked their prime lending rate by 25 basis points, pushing it up to 4.70% from 4.45%. Now, any old-timer in the trading arena knows that when banks shift their rates, it's not just numbers on paper—it ripples across the landscape, from...

Continue Reading
Beta Bionics: Investors on Edge, Legal Moves Underway

Updated Category News Views 81

A Tumultuous Time for Beta Bionics Investors Trouble's brewing for those holding Beta Bionics, Inc. (NASDAQ: BBNX) shares. This isn't just market jitters—it's a full-blown legal tussle. The shareholder-rights law honchos at Johnson Fistel are sounding the alarms, and investors better heed their call before the clock strikes November 3, 2026. There's a class action...

Continue Reading
Bitcoin Mortgages: APX Ushers in New Canadian Era

Updated Category News Views 0

Bitcoin Meets Canadian Mortgages: A Game Changer? Here's a scenario you didn't see coming: Bitcoin, the digital darling of the new millennium, now backing Canadian mortgages. If that doesn't get your financial senses tingling, maybe you haven't been paying attention. APX Lending, a pioneer in digital-asset-backed lending, is kicking open the doors to a fresh financial...

Continue Reading
Quanta Services Reports Record Q3 2026 Earnings

Updated Category News Views 51

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Continue Reading

Top 5 Most Recently Viewed Articles

BullFrog AI's Direct Offering Could Elevate Growth Potential

Updated Category News Views 160

Bullfrog AI's Financial Moves to Propel Future Growth BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) is setting the stage for substantial growth with its latest financial initiatives. WallachBeth Capital announced that the company has entered into a definitive agreement for the sale of approximately 1,565,000 shares of common stock through a registered direct offering....

Continue Reading
Aclarion Strengthens Market Position with New UK Director

Updated Category News Views 138

New Leadership in the UK Market Aclarion, Inc. is excited to announce the appointment of Dan Isherwood as the new UK Commercial Director. This strategic hire marks a significant milestone for the company, enhancing its capacity to penetrate the UK healthcare market effectively. With a robust background in HealthTech, Isherwood is poised to help drive the utilization of...

Continue Reading
Navigating Travel Insurance Amidst Potential Government Shutdowns

Updated Category News Views 98

Navigating Travel Insurance Amidst Potential Government Shutdowns As uncertainties loom regarding potential government shutdowns, travelers find themselves questioning how these events might disrupt their plans. A looming government shutdown often leads to numerous challenges, including staffing shortages at key agencies such as the FAA and TSA. These essential services,...

Continue Reading
Immuthera's Advisory Board: Pioneering New Frontiers in Diabetes Care

Updated Category News Views 146

Immuthera's Scientific Advisory Board: Innovation at the Forefront Immuthera, a leading name in the field of cell therapies, is thrilled to introduce its newly assembled Scientific Advisory Board. This esteemed group includes renowned experts like Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman. Their collective expertise will drive innovative solutions in...

Continue Reading
Astroport and Orbit Fab Partner to Advance Lunar Exploration

Updated Category News Views 128

Astroport and Orbit Fab Team Up for Lunar Exploration Astroport Space Technologies, Inc., a leader in advanced space exploration solutions, and Orbit Fab, Inc., renowned for in-space refueling and resource utilization, have announced an exciting partnership aimed at accelerating lunar infrastructure development. This collaboration marks a pivotal moment in the quest for...

Continue Reading